ClinicalTrials.gg
Status unknownNCT03552432ALTAIRUpdated Nov 14, 2018

The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography

A Phase 4 interventional study of Alirocumab in Coronary Artery Disease and Thin-cap fIbroatheroma, sponsored by Kobe University. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Kobe University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Coronary Artery Disease by Kobe University — 1 open to participants now, 1 under way, none of them phase 3. Coronary Artery Disease · Kobe University.

Started
2017
with 1 other
Phase 4
5 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Coronary Artery Disease by Kobe University, this one is one of 2 that started in 2017, is one of 5 in phase 4, and was the 5th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 10 studies in Coronary Artery Disease by Kobe University is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Kobe University, or all of them as a file.
02

Study summary

the purpose of this study is to show that alirocumab with statin therapy have a s tronger stabilizing effect on vulnerable plaque in coronary artery disease than statin alone administration

Read the detailed description

The investigators investigate to evaluate the efficacy of alirocumab for vulnerable plaque. The investigators enrolled the patient with standard statin therapy who were detected vulnerable plaque by optical coherence tomography, and categorized into two group; the patients with alirocumab and rosuvastatin were categorized alirocumab therapy group, and the patients with rosuvastatin alone were categorized standard statin therapy group. The investigators compare these two group for outcomes.

03

Conditions studied

  • Coronary Artery Disease
  • Thin-cap fIbroatheroma

Keywords

  • alirocumab
  • Thin-cap fIbroatheroma (TCFA)
  • vulnerable plaque
  • Optical Coherence Tomography (OCT)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who underwent PCI for ACS or stable coronary heart disease
  2. Patients with LDL-C ≥70 mg/dL under daily 10mg rosuvastatin
  3. Patients who have been had TCFA detected by OCT
  4. Patients aged ≥20 years old at PCI
  5. Patients who agree to be enrolled in the trial giving signed written

Exclusion criteria

Exclusion Criteria:

  1. Patients who have been treated previously with at least one dose of any anti-PCSK9 monoclonal antibody
  2. Patients had uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) between the time of PCI and randomization visit
  3. Known to alirocumab or rosuvastatin
  4. All to alirocumab and/or rosuvastatin as displayed in the respective national product labeling for these treatments
  5. Known history of hemorrhagic stroke
  6. Currently under treatment for cancer
  7. Patients on lipoprotein apheresis
  8. Patients with severe liver or renal dysfunction
  9. Pregnant or breast-feeding women
  10. Considered by the investigator as inappropriate for this study for any reason
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Alirocumab therapy group

    start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day

    Drug: Alirocumab

  • No intervention
    standard statin therapy group

    start with only rosuvastatin 10mg per day

Interventions

  • the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months

06

What researchers measure

Primary outcomes

  1. the change in fibrous cap thickness

    the absolute change in minimum fibrous-cap thickness between baseline and 36-week follow-up

    Time frame: 9 month

Secondary outcomes

  1. the change in fibrous cap thickness

    the percent change in minimum fibrous-cap thickness between baseline and 36-week follow-up

    Time frame: 9 month

  2. the change in lipid index

    absolute change in lipid index between baseline and 36-week follow-up

    Time frame: 9 month

  3. the change in lipid index

    percentage change in lipid index between baseline and 36-week follow-up

    Time frame: 9 month

  4. the change in lipid length,

    absolute change in lipid core length between baseline and 36-week follow-up

    Time frame: 9 month

  5. the change in lipid length,

    percentage change in lipid core length between baseline and 36-week follow-up

    Time frame: 9 month

  6. the change in mean lipid arc

    absolute change in mean lipid arc between baseline and 36-week follow-up

    Time frame: 9 month

  7. the change in mean lipid arc

    percentage change in mean lipid arc between baseline and 36-week follow-up

    Time frame: 9 month

  8. the change in max lipid arc

    absolute change in max lipid arc between baseline and 36-week follow-up

    Time frame: 9 month

  9. the change in max lipid arc

    percent change in max lipid arc between baseline and 36-week follow-up

    Time frame: 9 month

  10. the change in macrophage grade

    absolute change in summation of macrophage grade between baseline and 36-week follow-up. macrophage grade defined as an OCT macrophage grading system to semiquantify the bright spots based on axial and circumferential distribution, as follows: grade 0, no macrophage; grade 1, localized macrophage accumulation; grade 2, clustered accumulation \<1 quadrant; grade 3, clustered accumulation \>1 quadrant and ≦3 quadrants; and grade 4, clustered accumulation ≧3

    Time frame: 9 month

  11. the change in macrophage grade

    percentage change in summation of macrophage grade between baseline and 36-week follow-up. macrophage grade defined as an OCT macrophage grading system to semiquantify the bright spots based on axial and circumferential distribution, as follows: grade 0, no macrophage; grade 1, localized macrophage accumulation; grade 2, clustered accumulation \<1 quadrant; grade 3, clustered accumulation \>1 quadrant and ≦3 quadrants; and grade 4, clustered accumulation ≧3

    Time frame: 9 month

  12. the change in minimum lumen area

    absolute change in minimum lumen area between baseline and 36-week follow-up

    Time frame: 9 month

  13. the change in minimum lumen area

    percentage of change in minimum lumen area between baseline and 36-week follow-up

    Time frame: 9 month

  14. the number of thin-cap fibroatheroma

    change of the number of thin-cap fibroatheroma at 36-week follow-up

    Time frame: 9 month

  15. the change in total cholesterol

    absolute change in serum level of of total cholesterol between baseline and 36-week follow-up

    Time frame: 9 month

  16. the change in total cholesterol

    percent change in serum level of of total cholesterol between baseline and 36-week follow-up

    Time frame: 9 month

  17. the change in LDL-C

    absolute change in serum level of of LDL-C between baseline and 36-week follow-up

    Time frame: 9 month

  18. the change in LDL-C

    percentage change in serum level of of LDL-C between baseline and 36-week follow-up

    Time frame: 9 month

  19. the change in HDL-C

    absolute change in serum level of of HDL-C between baseline and 36-week follow-up

    Time frame: 9 month

  20. the change in HDL-C

    percentage change in serum level of of HDL-C between baseline and 36-week follow-up

    Time frame: 9 month

  21. the change in non-HDL-C

    absolute change in serum level of of non-HDL-C between baseline and 36-week follow-up

    Time frame: 9 month

  22. the change in non-HDL-C

    percentage change in serum level of of non-HDL-C between baseline and 36-week follow-up

    Time frame: 9 month

  23. the change in apolipoprotein B

    absolute change in serum level of of apolipoprotein B between baseline and 36-week follow-up

    Time frame: 9 month

  24. the change in apolipoprotein B

    percentage change in serum level of of apolipoprotein B between baseline and 36-week follow-up

    Time frame: 9 month

  25. the change in Lp(a)

    absolute change in serum level of of Lp (a) between baseline and 36-week follow-up

    Time frame: 9 month

  26. the change in Lp(a)

    percentage change in serum level of of Lp (a) between baseline and 36-week follow-up

    Time frame: 9 month

  27. the change in hs-CRP

    absolute change in serum level of hs-CRP between baseline and 36-week follow-up

    Time frame: 9 month

  28. the change in hs-CRP

    percentage change in serum level of hs-CRP between baseline and 36-week follow-up

    Time frame: 9 month

  29. the change in IL-1β

    absolute change in serum level of IL-1β between baseline and 36-week follow-up

    Time frame: 9 month

  30. the change in IL-1β

    percentage change in serum level of IL-1β between baseline and 36-week follow-up

    Time frame: 9 month

  31. the change in IL-6

    absolute change in serum level of IL-6 between baseline and 36-week follow-up

    Time frame: 9 month

  32. the change in IL-6

    percentage change in serum level of IL-6 between baseline and 36-week follow-up

    Time frame: 9 month

  33. the change in TNF-α

    absolute change in serum level of TNF-α between baseline and 36-week follow-up

    Time frame: 9 month

  34. the change in TNF-α

    percentage change in serum level of TNF-α between baseline and 36-week follow-up

    Time frame: 9 month

  35. the change in MCP-1

    absolute change in serum level of MCP-1 between baseline and 36-week follow-up

    Time frame: 9 month

  36. the change in MCP-1

    percentage change in serum level of MCP-1 between baseline and 36-week follow-up

    Time frame: 9 month

  37. the change in MMP-2

    absolute change in serum level ofMMP-2 between baseline and 36-week follow-up

    Time frame: 9 month

  38. the change in MMP-2

    percentage change in serum level ofMMP-2 between baseline and 36-week follow-up

    Time frame: 9 month

  39. the change in MMP-9

    absolute change in serum level of MMP-9 between baseline and 36-week follow-up

    Time frame: 9 month

  40. the change in MMP-9

    percentage change in serum level of MMP-9 between baseline and 36-week follow-up

    Time frame: 9 month

  41. the change in VCAM-1

    absolute change in serum level of VCAM-1between baseline and 36-week follow-up

    Time frame: 9 month

  42. the change in VCAM-1

    percentage change in serum level of VCAM-1 between baseline and 36-week follow-up

    Time frame: 9 month

  43. the change in ICAM-1

    absolute change in serum level of ICAM-1 between baseline and 36-week follow-up

    Time frame: 9 month

  44. the change in ICAM-1

    percentage change in serum level of ICAM-1 between baseline and 36-week follow-up

    Time frame: 9 month

  45. the change in free PCSK9

    absolute change in serum level of free PCSK9 between baseline and 36-week follow-up

    Time frame: 9 month

  46. the change in free PCSK9

    percentage change in serum level of free PCSK9 between baseline and 36-week follow-up

    Time frame: 9 month

07

Study locations

1 of 1 sites recruiting
  • Kobe University Graduate School of Medicine, Department of Cardiology
    Kobe, Hyogo 650-0017, Japan
    Recruiting
08

References and documents

Publications

  • Otake H, Sugizaki Y, Toba T, Nagano Y, Tsukiyama Y, Yanaka KI, Yamamoto H, Nagasawa A, Onishi H, Takeshige R, Nakano S, Matsuoka Y, Tanimura K, Kawamori H, Shinke T, Hirata KI. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin. J Cardiol. 2019 Mar;73(3):228-232. doi: 10.1016/j.jjcc.2018.11.012. Epub 2018 Dec 19. PubMed 30579806 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2017 (actual). Primary completion is estimated for Sep 2020, 37 months after the start.

Of 193 phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
Jun 11, 2018
StartActual
Aug 23, 2017
Primary completionEst.
Sep 30, 2020
CompletionEst.
Sep 30, 2021
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03552432
Lead sponsor
Kobe University
Responsible party
Hiromasa Otake (Senior Lecturer, Kobe University) — Principal investigator
First posted
Jun 11, 2018
Start date
Aug 23, 2017
Primary completion
Sep 30, 2020 (estimated)
Completion
Sep 30, 2021 (estimated)
Last update
Nov 14, 2018

Study contacts

Hiromasa Otake, M.D, Ph,D
Contact
hotake@med.kobe-u.ac.jp
+81-78-382-5846
Hiromasa Otake, M.D, Ph,D
principal investigator · Kobe University Graduate School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion